{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T08:51:41Z","timestamp":1784278301817,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effect of induction chemotherapy on liver function in patients with acute lymphoblastic leukemia is not well documented in Ethiopia. This study assessed hepatotoxicity in patients with acute lymphoblastic leukemia who were undergoing induction chemotherapy in Ethiopia. A 1-month cohort study was undertaken in forty patients with acute lymphoblastic leukemia, with measurements taken at the baseline, second, and fourth weeks. A Log 10 transformation was done because of the skewed distribution of liver function tests. Descriptive statistics such as mean and proportion were calculated. A mixed model ANOVA and Bonferroni post hoc test were computed. A <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.05 was declared to determine statistical significance. Clinically significant hepatotoxicity was observed in 15% of patients. Mild liver injury occurred in 5% of patients. The mean of all liver function tests increased significantly from pre-induction to post-induction. ALT levels were significantly higher in patients who received blood transfusions, but not in those who did not. Regardless of other factors, ALP level in children is significantly higher than in adults, although total bilirubin in adults is higher than in children. A significant proportion of patients had hepatotoxicity. During chemotherapy induction, the mean of all liver function tests rose significantly, but this elevation of serum liver function tests may be transient. Chemotherapy drugs should be given without causing a significant alteration in serum liver function tests. Continuous monitoring of patients should be required.<\/jats:p>","DOI":"10.1038\/s41598-022-17618-w","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T10:04:28Z","timestamp":1659434668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of liver function tests to identify hepatotoxicity among acute lymphoblastic leukemia patients who are receiving chemotherapy induction"],"prefix":"10.1038","volume":"12","author":[{"given":"Ayal Tsegaye","family":"Mekonnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temesgen Gebeyehu","family":"Wondmeneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"issue":"2","key":"17618_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"C-H Pui","year":"2006","unstructured":"Pui, C.-H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354(2), 166\u2013178 (2006).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"17618_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/dmpt-2016-0033","volume":"32","author":"M Lopez-Santillan","year":"2017","unstructured":"Lopez-Santillan, M., Iparraguirre, L., Martin-Guerrero, I., Gutierrez-Camino, A. & Garcia-Orad, A. Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene. Drug Metab. Pers. Ther. 32(1), 1\u20139 (2017).","journal-title":"Drug Metab. Pers. Ther."},{"issue":"4","key":"17618_CR3","first-page":"29","volume":"8","author":"M Mohseni","year":"2018","unstructured":"Mohseni, M., Uludag, H. & Brandwein, J. M. Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. Am. J. Blood Res. 8(4), 29 (2018).","journal-title":"Am. J. Blood Res."},{"issue":"1","key":"17618_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2354.2005.00513.x","volume":"14","author":"A Redaelli","year":"2005","unstructured":"Redaelli, A., Laskin, B., Stephens, J., Botteman, M. & Pashos, C. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur. J. Cancer Care 14(1), 53\u201362 (2005).","journal-title":"Eur. J. Cancer Care"},{"key":"17618_CR5","unstructured":"Society CC. Induction Treatments for Acute Lymphocytic Leukemia. https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/acute-lymphocytic-leukemia-all\/treatment\/induction#:~:text=Induction%20treatment%20is%20also%20called,complete%20remission%2C%20or%20complete%20response."},{"key":"17618_CR6","unstructured":"Booklet ACC. Understanding Chemotherapy. https:\/\/www.cancer.org.au\/assets\/pdf\/understanding-chemotherapy-booklet."},{"key":"17618_CR7","unstructured":"medicine P. All About Adult Acute Lymphocytic Leukemia (ALL). https:\/\/www.oncolink.org\/cancers\/leukemia\/leukemia-acute-lymphocytic-leukemia-all\/all-about-adult-acute-lymphocytic-leukemia-all."},{"issue":"3","key":"17618_CR8","first-page":"790","volume":"95","author":"ER Panzer-Gr\u00fcmayer","year":"2000","unstructured":"Panzer-Gr\u00fcmayer, E. R., Schneider, M., Panzer, S., Fasching, K. & Gadner, H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood J. Am. Soc. Hematol. 95(3), 790\u2013794 (2000).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"17618_CR9","volume-title":"Chemotherapy Toxicity in Patients with Acute Leukemia. Acute Leukemia-The Scientist's Perspective and Challenge","author":"JM Vagace","year":"2011","unstructured":"Vagace, J. M. & Gervasini, G. Chemotherapy Toxicity in Patients with Acute Leukemia. Acute Leukemia-The Scientist\u2019s Perspective and Challenge (Intechopen, 2011)."},{"issue":"3","key":"17618_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3350\/cmh.2014.20.3.317","volume":"20","author":"A Sharma","year":"2014","unstructured":"Sharma, A. et al. Chemotherapy induced liver abnormalities: An imaging perspective. Clin. Mol. Hepatol. 20(3), 317 (2014).","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"17618_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"Panel CPG","year":"2019","unstructured":"Panel CPG, Liver EAftSot. EASL clinical practice guidelines: Drug-induced liver injury. J. Hepatol. 70(6), 1222\u20131261 (2019).","journal-title":"J. Hepatol."},{"issue":"1","key":"17618_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3329\/jdmc.v29i1.51168","volume":"29","author":"M Jannat","year":"2020","unstructured":"Jannat, M., Morshed, A. A., Anwer, S. & Islam, S. Effect of chemotherapy on liver function during induction of remission in children with acute lymphoblastic leukemia receiving standard protocol. J. Dhaka Med. Coll. 29(1), 33\u201337 (2020).","journal-title":"J. Dhaka Med. Coll."},{"key":"17618_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/DHPS.S254644","volume":"12","author":"G Workalemahu","year":"2020","unstructured":"Workalemahu, G., Abdela, O. A. & Yenit, M. K. Chemotherapy-related adverse drug reaction and associated factors among hospitalized paediatric cancer patients at hospitals in North-West Ethiopia. Drug Healthc. Patient Saf. 12, 195 (2020).","journal-title":"Drug Healthc. Patient Saf."},{"issue":"3","key":"17618_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21767\/2575-7733.1000047","volume":"2","author":"A Azad","year":"2018","unstructured":"Azad, A. et al. Real world experience of drug induced liver injury in patients undergoing chemotherapy. J. Clin. Gastroenterol. Hepatol. 2(3), 18 (2018).","journal-title":"J. Clin. Gastroenterol. Hepatol."},{"issue":"4","key":"17618_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/00002018-200730040-00001","volume":"30","author":"G Abboud","year":"2007","unstructured":"Abboud, G. & Kaplowitz, N. Drug-induced liver injury. Drug Saf. 30(4), 277\u2013294 (2007).","journal-title":"Drug Saf."},{"issue":"2","key":"17618_CR16","first-page":"95","volume":"2","author":"A Grigorian","year":"2014","unstructured":"Grigorian, A. & O\u2019Brien, C. B. Hepatotoxicity secondary to chemotherapy. J. Clin. Transl. Hepatol. 2(2), 95 (2014).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"17618_CR17","first-page":"111","volume":"3","author":"A Satter","year":"2016","unstructured":"Satter, A., Khanam, A., Ibad, S. & Iftikhar, A. Drug induced hepatotoxicity after induction phase of chemotherapy in acute lymphoblastic leukemia patients. Eur. J. Biomed. Pharm. Res. 3, 111\u2013115 (2016).","journal-title":"Eur. J. Biomed. Pharm. Res."},{"issue":"02","key":"17618_CR18","first-page":"110","volume":"8","author":"T Islam","year":"2020","unstructured":"Islam, T. et al. Liver function tests in patients of acute leukemia before and after induction chemotherapy. J. Biosci. Med. 8(02), 110 (2020).","journal-title":"J. Biosci. Med."},{"issue":"7","key":"17618_CR19","first-page":"3155","volume":"17","author":"SH Yeang","year":"2016","unstructured":"Yeang, S. H., Chan, A., Tan, C. W., Lim, S. T. & Ng, H. J. Incidence and management of toxicity associated with LAsparaginase in the treatment of ALL and NK\/Tcell lymphoma: An observational study. Asian Pac. J. Cancer Prev. 17(7), 3155\u20133160 (2016).","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"17618_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/ejh.12600","volume":"96","author":"I Aldoss","year":"2016","unstructured":"Aldoss, I. et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur. J. Haematol. 96(4), 375\u2013380 (2016).","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"17618_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43046-021-00064-6","volume":"33","author":"HEA Elashtokhy","year":"2021","unstructured":"Elashtokhy, H. E. A., Elgohary, H. E., Eldeep, B. B., Gaber, S. M. & Elbedewy, T. A. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience. J. Egypt. Natl. Canc. Inst. 33(1), 1\u201310 (2021).","journal-title":"J. Egypt. Natl. Canc. Inst."},{"issue":"7","key":"17618_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.19.02292","volume":"38","author":"RQ Kloos","year":"2020","unstructured":"Kloos, R. Q. et al. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 38(7), 715\u2013724 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"17618_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-03208-9","volume":"11","author":"S Aslam","year":"2021","unstructured":"Aslam, S., Ameer, S., Shabana, N. & Ahmed, M. Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol. Sci. Rep. 11(1), 1\u20138 (2021).","journal-title":"Sci. Rep."},{"issue":"4","key":"17618_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1078155217701291","volume":"24","author":"TN Christ","year":"2018","unstructured":"Christ, T. N., Stock, W. & Knoebel, R. W. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J. Oncol. Pharm. Pract. 24(4), 299\u2013308 (2018).","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"3","key":"17618_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1089\/jayao.2015.0014","volume":"4","author":"N Boissel","year":"2015","unstructured":"Boissel, N. & Sender, L. S. Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: A focus on asparaginase. J. Adolesc. Young Adult Oncol. 4(3), 118\u2013128 (2015).","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"17618_CR26","first-page":"510","volume":"4","author":"A Jahalla","year":"2017","unstructured":"Jahalla, A. & Alameen, A. Assessment of liver function before and after L-asparaginase therapy in acute lymphoblastic leukemia. Eur. J. Biomed. Pharm. Sci. 4, 510\u2013513 (2017).","journal-title":"Eur. J. Biomed. Pharm. Sci."},{"issue":"4","key":"17618_CR27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4103\/ijmpo.ijmpo_106_18","volume":"40","author":"S Gupta","year":"2019","unstructured":"Gupta, S. et al. Effect of dose and schedule of L-asparaginase administration on early minimal residual disease in acute lymphoblastic leukemia. Indian J. Med. Paediatr. Oncol. 40(4), 496\u2013500 (2019).","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"17618_CR28","unstructured":"Child TACotRaWot. Overarching Definition of the Child in Africa, 1990. http:\/\/www.africanchildforum.org\/clr\/Harmonisation%20of%20Laws%20in%20Africa\/other-documents-harmonisation_1_en.pdf."},{"issue":"6","key":"17618_CR29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal, G. P. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89(6), 806\u2013815 (2011).","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17618-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17618-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:21:12Z","timestamp":1669353672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17618-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17618"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17618-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13215"}}